Frederik B. Thomsen
Frederik B. Thomsen
Unknown affiliation
Verified email at regionh.dk - Homepage
TitleCited byYear
Active surveillance for clinically localized prostate cancer––A systematic review
FB Thomsen, K Brasso, LH Klotz, MA Røder, KD Berg, P Iversen
Journal of surgical oncology 109 (8), 830-835, 2014
1422014
ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer
KD Berg, B Vainer, FB Thomsen, MA Røder, TA Gerds, BG Toft, K Brasso, ...
European urology 66 (5), 851-860, 2014
962014
Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis
K Brasso, FB Thomsen, AJ Schrader, SC Schmid, D Lorente, M Retz, ...
European urology 68 (2), 317-324, 2015
922015
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
FB Thomsen, MA Røder, P Rathenborg, K Brasso, M Borre, P Iversen
Scandinavian journal of urology 48 (3), 268-275, 2014
592014
Active surveillance can reduce overtreatment in patients with low-risk prostate cancer
FB Thomsen, MA Røder, H Hvarness, P Iversen, K Brasso
Dan Med J 60 (2), A4575, 2013
512013
Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin
J Lauritsen, MGG Kier, M Bandak, MS Mortensen, FB Thomsen, ...
Journal of Clinical Oncology 34 (13), 1492-1499, 2016
312016
Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study
FB Thomsen, K Brasso, IJ Christensen, JE Johansson, A Angelsen, ...
European journal of cancer 51 (10), 1283-1292, 2015
212015
Improved survival for patients with de novo metastatic prostate cancer in the last 20 years
KD Berg, FB Thomsen, MK Mikkelsen, IJ Ingimarsdóttir, RB Hansen, ...
European Journal of Cancer 72, 20-27, 2017
182017
Prostate‐specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer
FB Thomsen, IJ Christensen, K Brasso, MA Røder, P Iversen
BJU international 113 (5b), E98-E105, 2014
152014
Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older
FB Thomsen, M Bandak, MF Thomsen, J Lauritsen, IJ Christensen, ...
Cancer 120 (1), 43-51, 2014
152014
Active surveillance for localized prostate cancer: an analysis of patient contacts and utilization of healthcare resources
FB Thomsen, KD Berg, MA Røder, P Iversen, K Brasso
Scandinavian journal of urology 49 (1), 43-50, 2015
142015
The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading–a matched‐pair analysis
KD Berg, FB Thomsen, C Nerstrøm, MA Røder, P Iversen, BG Toft, ...
BJU international 117 (6), 883-889, 2016
132016
Association of radical local treatment with mortality in men with very high-risk prostate cancer: a semiecologic, nationwide, population-based study
P Stattin, F Sandin, FB Thomsen, H Garmo, D Robinson, IF Lissbrant, ...
European urology 72 (1), 125-134, 2017
122017
Prognostic implications of 2005 Gleason grade modification. Population‐based study of biochemical recurrence following radical prostatectomy
FB Thomsen, Y Folkvaljon, K Brasso, S Loeb, D Robinson, L Egevad, ...
Journal of surgical oncology 114 (6), 664-670, 2016
112016
Risk of malignant melanoma in men with prostate cancer: Nationwide, population‐based cohort study
FB Thomsen, Y Folkvaljon, H Garmo, D Robinson, S Loeb, C Ingvar, ...
International journal of cancer 138 (9), 2154-2160, 2016
112016
Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study
FB Thomsen, K Brasso, KD Berg, TA Gerds, JE Johansson, A Angelsen, ...
Annals of Oncology 27 (3), 460-466, 2015
112015
The predictive value of ERG protein expression for development of castration‐resistant prostate cancer in hormone‐naïve advanced prostate cancer treated with primary androgen …
KD Berg, MA Røder, FB Thomsen, B Vainer, TA Gerds, K Brasso, ...
The Prostate 75 (14), 1499-1509, 2015
112015
Risk factors associated with positive surgical margins following radical prostatectomy for clinically localized prostate cancer: can nerve-sparing surgery increase the risk?
MA Røder, FB Thomsen, IJ Christensen, BG Toft, K Brasso, B Vainer, ...
Scandinavian journal of urology 48 (1), 15-20, 2014
112014
ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer
KD Berg, K Brasso, FB Thomsen, MA Røder, H Holten-Rossing, BG Toft, ...
Journal of clinical pathology 68 (10), 788-794, 2015
102015
Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center
FB Thomsen, MK Mikkelsen, RB Hansen, AH Krug, A Glenthøj, P Stattin, ...
Acta Oncologica 55 (12), 1456-1460, 2016
92016
The system can't perform the operation now. Try again later.
Articles 1–20